Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Mary Katherine Anderson, Valerie Shostrom, Robert Bociek, Snegha Ananth, Matthew Lunning, Julie Vose, Christopher D'Angelo

Blood (2025) 146 (Supplement 1): 8021.

https://doi.org/10.1182/blood-2025-8021

Published: 2025

Journal Articles

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Krish Patel, Matthew Lunning, Konstantinos Sdrimas, Minoo Battiwalla, Uttam Rao, Yi Lin, Sami Ibrahimi, Jennifer L. Crombie, Sairah Ahmed, Iris Isufi, Matthew Frigault, David Bernasconi, Debasmita Roy, Marcelo Pasquini, Bradley D. Hunter

Blood (2025) 146 (Supplement 1): 5482.

https://doi.org/10.1182/blood-2025-5482

Published: 2025

Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2025-5351

Published: 2025

Journal Articles

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Blood (2025) 146 (Supplement 1): 893.

https://doi.org/10.1182/blood-2025-893

Published: 2025

Journal Articles

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Blood (2025) 146 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2025-1837

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Blood (2025) 146 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2025-5384

Published: 2025

Journal Articles

The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)

Blood (2025) 146 (Supplement 1): 518.

https://doi.org/10.1182/blood-2025-518

Published: 2025

Journal Articles

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Blood (2025) 146 (Supplement 1): 6294.

https://doi.org/10.1182/blood-2025-6294

Published: 2025

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Blood (2025) 146 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2025-3739

Published: 2025

Journal Articles

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2025-3710

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study

Blood (2025) 146 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2025-1967

Published: 2025

Journal Articles

Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy

Aaron Murray, Valerie Shostrom, Robert Bociek, Snegha Ananth, Julie Vose, Matthew Lunning, Tanya Wildes, Christopher D'Angelo

Blood (2025) 146 (Supplement 1): 785.

https://doi.org/10.1182/blood-2025-785

Published: 2025

Journal Articles

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Blood (2025) 146 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2025-3663

Published: 2025

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Abhinav Deol, Taha Mahdi Salih Al-Juhaishi, Premal D. Lulla, Michael T. Byrne, Carol Wong, Cara Bickers, Trever Greene, Lilly Wong, Bertha Villa, Deepa Patel, Bahram Bob Valamehr, Rebecca Elstrom, Matthew Lunning

Blood (2024) 144 (Supplement 1): 6543.

https://doi.org/10.1182/blood-2024-198684

Published: 2024

Journal Articles

Long Term Follow up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma

Sandra Frimpong, Valerie K Shostrom, Robert Gregory Bociek, Matthew Lunning, Christopher D' Angelo, James Olen Armitage, Julie M. Vose

Blood (2024) 144 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2024-201621

Published: 2024

Journal Articles

Analysis of Surveillance Imaging and Outcomes for Relapsed CNS Lymphoma Using Novel Agents

Matthew Gromowsky, Shristi Upadhyay Banskota, Smriti Sharma, Robin High, Robert Gregory Bociek, Matthew Lunning, Julie M. Vose, Christopher D'Angelo

Blood (2024) 144 (Supplement 1): 7777.

https://doi.org/10.1182/blood-2024-206305

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study

Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma

Long Term Follow up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma

Analysis of Surveillance Imaging and Outcomes for Relapsed CNS Lymphoma Using Novel Agents

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only